WHO Pharmaceuticals Newsletter 2005, No. 05
(2005; 13 pages) View the PDF document
Table of Contents
Open this folder and view contentsREGULATORY MATTERS
Close this folderSAFETY OF MEDICINES
View the documentEstrogen/ progestin weekly patch - Higher levels of estrogen than birthcontrol pills
View the documentFactor VIII (FVIII) recombinant products - Risk of inhibitor development in previously treated patients
View the documentLiqiang 4 dietary supplement - Presence of glyburide
View the documentMeningococcal vaccine - Reports of Guillain-Barré Syndrome
View the documentMenze Qianweishu slimming herbs capsule - Found to contain sibutramine
View the documentMethadone - Cardiac vigilance recommended
View the documentNimodipine - Serious events due to IV use of oral formulations
View the documentOseltamivir - Safety update
Open this folder and view contentsPROBLEMS OF CURRENT INTEREST
Open this folder and view contentsFEATURE
 

Liqiang 4 dietary supplement - Presence of glyburide

Canada. Health Canada is warning consumers that ‘Liqiang 4 dietary supplement capsules’ contain glyburide, a prescription drug used to treat type 2 diabetes. The supplement could thus have life-threatening consequences in diabetics and in individuals with low blood sugar if used without medical supervision. Liqiang 4 capsules, promoted for use in the control of diabetes, are not approved for sale in Canada. However, consumers could probably buy them through mail-order or over the Internet. Consumers are advised to immediately stop using these products and to seek medical attention, especially if they are currently being treated with anti-diabetic drugs.

Reference:

Advisory. Health Canada, 25 October 2005 (http://www.hc-sc.gc.ca).

to previous section to next section
 

Last updated: May 3, 2013